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Abstract
Introduction: Adenosine is the most widely used vasodilator stress agent for Cardiovascular Magnetic Resonance
(CMR) perfusion studies. With the standard dose of 140 mcg/kg/min some patients fail to demonstrate
characteristic haemodynamic changes: a significant increase in heart rate (HR) and mild decrease in systolic blood
pressure (SBP). Whether an increase in the rate of adenosine infusion would improve peripheral and, likely,
coronary vasodilatation in those patients is unknown. The aim of the present study was to assess the tolerance and
safety of a high-dose adenosine protocol in patients with inadequate haemodynamic response to the standard
adenosine protocol when undergoing CMR perfusion imaging.
Methods: 98 consecutive patients with known or suspected coronary artery disease (CAD) underwent CMR
perfusion imaging at 1.5 Tesla. Subjects were screened for contraindications to adenosine, and an
electrocardiogram was performed prior to the scan. All patients initially received the standard adenosine protocol
(140 mcg/kg/min for at least 3 minutes). If the haemodynamic response was inadequate (HR increase < 10 bpm or
SBP decrease < 10 mmHg) then the infusion rate was increased up to a maximum of 210 mcg/kg/min (maximal
infusion duration 7 minutes).
Results: All patients successfully completed the CMR scan. Of a total of 98 patients, 18 (18%) did not demonstrate
evidence of a significant increase in HR or decrease in SBP under the standard adenosine infusion rate. Following
the increase in the rate of infusion, 16 out of those 18 patients showed an adequate haemodynamic response.
One patient of the standard infusion group and two patients of the high-dose group developed transient
advanced AV block. Significantly more patients complained of chest pain in the high-dose group (61% vs. 29%,
p = 0.009). On multivariate analysis, age > 65 years and ejection fraction < 57% were the only independent
predictors of blunted haemodynamic responsiveness to adenosine.
Conclusions: A substantial number of patients do not show adequate peripheral haemodynamic response to
standard-dose adenosine stress during perfusion CMR imaging. Age and reduced ejection fraction are predictors of
inadequate response to standard dose adenosine. A high-dose adenosine protocol (up to 210 mcg/kg/min) is well
tolerated and results in adequate haemodynamic response in nearly all patients.
Introduction
First pass perfusion cardiovascular magnetic resonance
(CMR) is routinely performed under vasodilatory phar-
macological stress with either adenosine or dipyridamole
[1,2]. Adenosine is the most widely used vasodilator
agent because it is safe, well tolerated, and easily con-
trolled [3]. It generates systemic vasodilatation and
reflex sympatho-excitation with consequent mild
decrease in systolic blood pressure, slight increase in
heart rate, and modest increase in double product [4].
As a potent coronary vasodilator, adenosine causes up
to a 4-fold increase in myocardial blood flow in areas
supplied by normal coronary arteries. In contrast, in the
presence of epicardial coronary stenoses, flow inhomo-
geneities give rise to regional perfusion defects during
the first pass of a gadolinium based contrast [1].
With the standard adenosine dose of 140 mcg/kg/min
most, but not all, patients develop maximal vasodilatation
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vasodilatation however, the adequacy of coronary vasodi-
latation is questioned. Whether this inadequate cardio-
vascular response would respond to an increase in the
rate of adenosine infusion is unknown. It is also unclear
whether a high-dose adenosine infusion protocol is safe
and would be tolerated by patients undergoing stress per-
fusion CMR. We hypothesized that an increase in the
adenosine infusion rate up to 210 mcg/kg/min would
result in an improved peripheral haemodynamic response
in perfusion CMR subjects who failed to show character-
istic changes in blood pressure and heart rate with the
standard adenosine dose (140 mcg/kg/min).
Methods
The study population consisted of patients with known
or suspected coronary artery disease (CAD) who under-
went adenosine stress perfusion CMR imaging for clinical
purposes. All patients gave informed consent before the
CMR scan. All subjects were initially screened for the
presence of contraindications to adenosine, which
include asthma, unstable angina or acute myocardial
infarction within two weeks of the study, 2
nd or 3
rd
degree atrioventricular (AV) block and bifascicular block.
A 12-lead ECG was performed before the CMR scan. All
patients were asked to abstain from caffeine for at least
12 hours prior to the scan. However, patients who
reported caffeine intake within the last 12 hours were
still included in the study. Prior to the CMR scan, a phy-
sician carefully explained the procedure to subjects, with
emphasis on potential adenosine-related symptoms. Sub-
jects were continuously monitored with peripheral
oxygen saturation, heart rate and 2-lead ECG throughout
the CMR scan. Systemic blood pressure was periodically
checked at every minute during adenosine stress and
15 min after the end of the infusion. The monitor tracing
during the CMR scan does not allow for identification of
1
st or Wenckebach 2
nd degree AV block and therefore
only advanced degrees of AV block (Mobitz II 2
nd degree
and 3
rd degree) were noted. Each subject was questioned
during and immediately after termination of adenosine
infusion, specifically for the occurrence of the following
symptoms: shortness of breath or dyspnea, chest pain
and other minor symptoms (flushing, nausea, headache).
At least two clinicians trained in cardiopulmonary resus-
citation and CMR evacuation procedures were present
during the adenosine infusion.
Adenosine infusion protocol
All patients initially had the standard adenosine (Ade-
noscan®, Sanofi-Synthelabo) infusion dose of 140 mcg/
kg/min for at least 3 minutes through an antecubital
vein using a syringe pump (Graseby® 3500). If after
3 minutes of continuous infusion at the standard rate,
the haemodynamic response to adenosine was inade-
quate (heart rate increase < 10 beats per minute or sys-
tolic blood pressure decrease < 10 mmHg, and minimal
or no reported side effects from the patient) then the
infusion rate was increased to 170 mcg/kg/min for a
further 2 minutes. The absence or minimal presence of
classical adenosine side effects was not a criterion to
increase the dose if an adequate haemodynamic
response was evidenced. If still patients failed to show
evidence of peripheral vasodilatation then the infusion
was increased to a maximum of 210 mcg/kg/min for a
further 2 minutes. The infusion was discontinued if
patients developed persistent or symptomatic 3
rd degree
AV block, severe hypotension (systolic blood pressure
<90 mmHg) or bronchospasm. The attending physicians
had aminophylline for adenosine receptor antagonism
and nitroglycerine for persistent chest pain readily avail-
able, and a fully equipped resuscitation trolley with defi-
brillator was easily accessible.
CMR protocol
All CMR examinations were performed with subjects in
a supine position on a 1.5 MR Tesla (Siemens Avanto,
Erlangen, Germany) with a 32-element phased-array
coil. During the last minute of adenosine infusion a
gadolinium-based contrast agent (Gadodiamide, Omnis-
can®, GE Healthcare or Gadoterate meglumine,
Dotarem®, Guerbet S.A.) was administered intravenously
at 0.075 mmol/kg body weight (injection rate 4 ml/s),
followed by a 20 ml saline flush at the same rate. Perfu-
sion imaging was performed every cardiac cycle during
the first pass, using a T1-weighted fast (spoiled) gradient
echo sequence (echo time 1.05 ms, repetition time 2 ms,
saturation recovery time 100 ms, voxel size 2.3 × 2.8 ×
10 mm; flip angle 12°). Three or four short-axis slices,
positioned from the base to the apex of the left ventri-
cle, were obtained. The same imaging sequence was
repeated at least 10 minutes later without adenosine to
obtain perfusion images at rest. For assessment of left
ventricular function, steady-state free-precession cine
images (TE/TR 1.1/2.6 ms, voxel size 2.0 × 2.0 × 7 mm,
flip angle 55°) were acquired in three long-axis views,
and a short-axis stack to obtain coverage of the entire
left ventricle. Analysis of left ventricular function was
performed with Argus Syngo MR software (version B15,
Siemens Healthcare, Erlangen, Germany) using the
short-axis SSFP images as previously described [7]. The
following left ventricular parameters were thereby deter-
mined: end-diastolic volume, end-systolic volume, ejec-
tion fraction and myocardial mass.
Coronary angiography
Based on clinical criteria, a proportion of patients
underwent coronary angiography. The decision to
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abnormal perfusion CMR scan was left at the discretion
of the referring consultant cardiologist. Significant CAD
was defined visually as the presence of at least one ste-
nosis of > 50% diameter in any of the main epicardial
coronary arteries or their branches with a diameter of
≥ 2 mm.
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation. Categorical variables are expressed as counts
and percentages. All continuous variables were found to
be normally distributed by the Kolmogorov-Smirnov test.
Differences in continuous variables between the standard-
and high-dose groups were assessed by independent
student’s t-test. One-way analysis of variance (ANOVA)
followed by post-hoc Bonferroni analysis was used to com-
pare the haemodynamic response to stress in the high-
dose group at several time points (baseline, standard dose
and maximum infusion rate). Comparisons of categorical
variables between groups were performed by c
2 test or
Fisher’s exact test as appropriate. We used binary logistic
regression analysis to identify potential predictors of
inadequate response to standard adenosine dose. Receiver
operator characteristic analysis was used to identify cut-
offs for continuous variables such as age and ejection frac-
tion. Based on those cut-off values, ejection fraction and
age were entered into the regression model as dichoto-
mous variables. A probability value of p < 0.05 was consid-
ered significant and two-tailed p values were used for all
statistics. Statistical analyses were performed using
MedCalc for Windows, version 11.3 (MedCalc Software,
Mariakerke, Belgium) and the SPSS Statistics software
(version 17.0; SPSS Inc., Chicago, Ill., USA).
Results
Patient characteristics
Data were collected from 98 consecutive subjects (mean
age 58 ± 14 years, range 17-84 years) of whom 66 (67%)
were men. Of the 98 subjects enrolled, 53 (54%) had a
coronary angiogram. Of these 53 patients undergoing
coronary angiography, 26 (49%) were found to have sig-
nificant CAD: 20 single-vessel and 6 multi-vessel dis-
ease. The majority of our patients had undergone
coronary angiography before the CMR scan. Specifically,
36 patients (68%) had a coronary angiogram before the
CMR scan and 17 after the scan (32%). Of those 53
patients who underwent coronary angiography, 13 (25%)
had normal perfusion on CMR, 32 (60%) had perfusion
defects at stress and 8 (15%) had defects at stress corre-
sponding to LGE without evidence of peri-infarct
ischaemia. Table 1 shows the baseline characteristics of
the subjects, and figure 1 shows a typical example from
a first pass perfusion study.
Haemodynamic response to standard dose adenosine
Overall, 80 patients (82%) had an adequate response to
the standard adenosine infusion rate of 140 mcg/kg/min
with a significant increase in heart rate (p < 0.001) and
rate pressure product (p < 0.001). There were minimal
changes in systolic or diastolic blood pressure measure-
ments. The mean duration of adenosine infusion was
246 ± 35 seconds (Table 2).
Haemodynamic response to high dose adenosine
Eighteen patients (18%) failed to show signs of adequate
haemodynamic response during standard-dose adenosine
infusion. Following an increase in the dose of adenosine
(up to 170 mcg/kg/min in 6 patients; and up to 210 mcg/
kg/min in 12 patients) 16 out of these 18 patients showed
an improved haemodynamic response with greater rise in
heart rate (p = 0.011) and a mild drop in systolic blood
pressure (p = 0.57). There was a trend towards a signifi-
cant increase to rate pressure product at maximum adeno-
sine rate compared to baseline (p = 0.07). The mean
duration of adenosine infusion was significantly longer for
the high-dose group (387 ± 46 seconds; p < 0.001) com-
pared to the standard dose group (246 ± 35 seconds).
Table 2 shows the haemodynamic effects of adenosine in
both groups. Of the 80 patients who received standard
dose adenosine 50 patients (63%) had abnormal perfusion
on CMR (defined as any defect at stress irrespective of the
LGE findings). Similarly, of the 18 patients who received
high dose adenosine 10 (56%) patients had abnormal per-
fusion on CMR (p = 0.6).
Adverse events
There were no deaths, myocardial infarctions, or epi-
sodes of bronchospasm or pulmonary edema in our
cohort as a result of the adenosine stress. Transient
advanced AV block (Mobitz II 2
nd degree and 3
rd
degree) occurred in 3 subjects (8%), of whom 2 had the
high-dose adenosine infusion and 1 the standard dose
(p = 0.07). There were no sustained episodes of
advanced AV block. More patients complained of chest
pain/tightness in the high-dose group (p = 0.009), but
these were short-lived, and sublingual nitrate adminis-
tration was not required in any patients. There were no
significant differences in the incidence of other common
adenosine adverse effects such as shortness of breath,
headache or flushing between the two groups. All these
symptoms resolved shortly after termination of adeno-
sine infusion and no aminophylline reversal was
required. The adverse effects of adenosine in our cohort
are summarised in Table 3.
Predictors of non-response to standard adenosine dose
Patients who showed an inadequate haemodynamic
response to standard adenosine infusion rate were older
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over, non-responders to standard adenosine dose had
significantly lower ejection fractions compared to
patients in the standard infusion group (Table 1). There
were no differences between the two groups with refer-
ence to previous caffeine intake (p = 0.31). Receiver
operator characteristic analysis showed that an age cut-
off ≥ 65 years had 72% sensitivity and 75% specificity
(area under the curve 0.753 ± 0.06, p = 0.0001) to pre-
dict inadequate response to adenosine at the standard
infusion dose of 140 μg/kg/min (Figure 2). Similarly, an
ejection fraction cut-off of < 57% had 67% sensitivity
and 80% specificity (area under the curve 0.717 ± 0.08,
p = 0.0083) to identify non-responders (Figure 2).
Table 1 Characteristics of Study Population
Standard dose group (n = 80) High dose group (n = 18) p-value
Age 56 ± 14 67 ± 10 0.001
Male 53 (66%) 13 (72%) 0.63
Height 172 ± 10 171 ± 11 0.89
Weight 84 ± 16 84 ± 19 0.98
BSA 1.99 ± 0.21 1.99 ± 0.28 0.95
Caffeine < 12 hours prior to scan 4 (5%) 2 (11%) 0.31
Hypertension 34 (43%) 7 (39%) 0.78
Diabetes 4 (5%) 4 (22%) 0.036
Hyperlipidaemia 35 (44%) 9 (50%) 0.63
Family history of CAD 12 (15%) 2 (11%) 1.00
Current Smoking 5 (6%) 0 (0%) 0.58
Coronary angiography 42 (53%) 11 (61%) 0.54
Single vessel CAD 14 (33%) 6 (38%) 0.49
Multi-vessel CAD 2 (5%) 4 (22%) 0.013
End-diastolic volume (ml) 157 ± 46 183 ± 61 0.10
End-systolic volume (ml) 59 ± 38 99 ± 62 0.018
Ejection fraction (%) 65 ± 13 52 ± 19 0.007
Mass index (gr/m
2) 71 ± 21 72 ± 18 0.79
B-blockers 22 (28%) 6 (33%) 0.62
Ca-inhibitors 13 (16%) 4 (22%) 0.51
ACE-inhibitors 32 (40%) 9 (50%) 0.44
Statins 32 (40%) 9 (50%) 0.44
Aspirin 22 (28%) 8 (44%) 0.16
Values are mean ± standard deviation or number (percent).
ACE, angiotensin converting enzyme; BSA, body surface area; CAD, coronary artery disease.
Figure 1 A representative example from a CMR perfusion scan during high dose adenosine stress. This is a 69-year-old diabetic patient
with a significant stenosis of the left anterior descending coronary artery. Note the marked perfusion defect in the septum and anterior wall
(arrows). The resting perfusion scan (panel B) is normal and shows homogeneous enhancement in all myocardial regions.
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age ≥ 65 years (OR 6.4-95% CI 1.9-22.0-p = 0.0032) and
EF< 57% (OR 7.6-95% CI 2.2-25.4-p = 0.0011) were the
two independent predictors of inadequate haemody-
namic response to standard adenosine dose.
Discussion
The present study is the first to demonstrate the feasibil-
ity and safety of high-dose adenosine in patients with
known or suspected CAD undergoing stress perfusion
CMR. Our findings suggest that a substantial number of
patients (18% in our cohort) do not show a sufficient hae-
modynamic response to adenosine stress. Independent
predictors of an inadequate response to the standard ade-
nosine dose of 140 mcg/kg/min were: age above 65 years
and ejection fraction less than 57%. The attenuated
response to adenosine can be surmounted by increasing
adenosine dose up to 210 mcg/kg/min without significant
adverse events. Our study has important clinical implica-
tions because a reduced peripheral haemodynamic
response to standard dose intravenous administration of
adenosine may reflect similarly inadequate effects on cor-
onary vasodilatation, thereby affecting the diagnostic
reliability of CMR perfusion imaging.
Adenosine is a powerful vasoactive substance. Activation
of cardiac A2A and A2B adenosine receptors dilates the
coronary and peripheral arterial beds (with the exception
of renal glomerular afferent arteriole), increases myocar-
dial blood flow, and causes sympatho-excitation [4]. These
effects cause mild decrease in blood pressure and barore-
ceptor-mediated reflex tachycardia [8,9]. The majority of
patients reach near maximal coronary vasodilatation and
show signs of sufficient peripheral vasodilatory response
after 2-3 minutes of adenosine infusion at the standard
dose of 140 mcg/kg/min. However, as previous studies
have demonstrated, some patients show reduced vasodila-
tor response to the standard dose [4-6].
In our study 18% of patients showed inadequate per-
ipheral haemodynamic response to the standard infusion
dose. Similarly, Wilson et al. measured coronary blood
flow invasively using Doppler and found that 16% of their
subjects who received adenosine at 140 mcg/kg/min did
not achieve maximal coronary hyperaemia as compared
to that produced with papaverine [4]. The mechanism of
this phenomenon is not well understood, but it is inter-
esting that similar differences in adenosine responsive-
ness have also been reported in dogs [10]. Impairment of
the baroreceptor reflex, resulting in decreased vascular
reactivity in response to vasodilator stimuli is a possible
cause of reduced heart rate response. As previously
shown, diabetic or elderly patients have attenuated reflex
tachycardia in response to vasodilator-induced decreased
blood pressure, possibly attributable to autonomic dys-
function [5,11]. Indeed, our study patients who showed
reduced haemodynamic response were significantly older
a n dw e r em o r el i k e l yt oh a v eh i s t o r yo fd i a b e t e sm e l l i t u s
than those with normal response to standard adenosine.
Moreover, a left ventricular ejection fraction of less than
57% was also associated with inadequate peripheral hae-
modynamic response. This may be an effect of the
already increased sympathetic nervous activity known to
be present in heart failure. It is well known that patients
with heart failure have high resting peripheral vasomotor
tone which makes them less responsive to the vasodilator
Table 2 Haemodynamic Parameters at Rest and During Adenosine Stress
Standard dose Adenosine
(n = 80)
High dose Adenosine
(n = 18)
Rest Peak p-value Rest 140 μg/kg/min Peak p-value
HR(bpm) 70 ± 13 96 ± 16 < 0.001 66 ± 12 75 ± 11 81 ± 18* 0.011
SBP (mmHg) 137 ± 18 139 ± 19 0.21 139 ± 23 134 ± 24 132 ± 22 0.68
DBP (mmHg) 80 ± 12 81 ± 12 0.55 82 ± 12 79 ± 11 77 ± 14 0.57
RPP 9639 ± 2399 13304 ± 2781 < 0.001 8975 ± 1909 9945 ± 1694 10672 ± 2787 0.07
* p < 0.05 vs. rest.
DBP, diastolic blood pressure; HR, heart rate; RPP, rate pressure product; SBP, systolic blood pressure.
Table 3 Adverse Effects of Adenosine
Standard dose Adenosine
(n = 80)
High dose Adenosine
(n = 18)
p-value
Chest pain 23 (29%) 11 (61%) 0.009
Shortness of breath 19 (24%) 6 (33%) 0.40
Flushing, headache or dizziness 29 (37%) 9 (50%) 0.28
Mobitz II 2
nd or 3
rd degree atrioventricular block 1 (1%) 2 (11%) 0.09
Angina requesting sublingual nitrates 0 (0%) 0 (0%) -
Scan abandoned during adenosine on subject’s request 0 (0%) 0 (0%) -
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tion between high catecholamine levels and endogenous
adenosine formation which acts as a negative feedback
system in patients with heart failure [13]. Lastly, besides
physiological considerations, genetic factors are likely to
play an important role in determining response to adeno-
sine. Potency of adenosine is strongly influenced by the
number of adenosine receptors expressed in myocardial
cells, the predominant type of receptor expressed, as well
as the type of response that is measured from adenosine
stimulation [14-17].
Our data suggest that there is a clear dose-response rela-
tion and when patients fail to show adequate vasomotor
responsiveness, a further increase in adenosine dose can
induce signs of improved peripheral hemodynamic effect.
This dose-dependent vasodilator effect is also supported
by previous studies using intravenous or intracoronary
doses of adenosine [18-21]. Reyes and colleagues have
used a high-dose adenosine protocol (210 mcg/kg/min) to
overcome caffeine antagonism in patients undergoing
myocardial perfusion scintigraphy [22]. In total, 18
patients received the high dose after 200 mg of caffeine
intake. The increased adenosine dose was well tolerated
and was effective to surmount the inhibitory effect of caf-
feine. Our study is the first to use high dose adenosine in
patients undergoing perfusion CMR imaging who fail to
show an adequate cardiovascular response, irrespective of
caffeine use. Although our patient cohort is small, all 18
patients who received high dose adenosine infusion toler-
ated it well without significant adverse clinical events. We
did not measure caffeine levels in our patient population
and, therefore, recent caffeine intake, despite the clear
instructions to avoid it for 24 hours, cannot be excluded.
However, as previously shown, even patients who con-
sume coffee 1-2 hours before the scan and reach peak
levels of caffeine during the infusion of adenosine may
demonstrate similar hemodynamic response to stress with
patients who had no caffeine [22-24]. Therefore, we
believe that the insufficient response to adenosine stress
which 18 of our patients showed is unlikely to be due to
previous caffeine intake.
Previous studies looking into the relation between the
peripheral hemodynamic actions of adenosine and its
coronary vasodilator effect have shown that despite a
lack of peripheral response to adenosine, coronary vaso-
dilatation remains adequate for the purpose of myocar-
dial perfusion imaging [25]. This observation would
suggest that a further increase to adenosine dose in
order to induce better systemic and coronary vasodilata-
tion to non-responders to standard dose is not needed.
However, there are important differences between our
study and the aforementioned study by Mishra and col-
leagues. First of all, we prospectively defined ‘non-
responders’ to standard adenosine dose (HR rise < 10
bpm, SBPdrop < 10 mmHg) whereas Mishra and collea-
gues retrospectively looked into the lower tertile which
had an average HR change of 13 bpm. Notwithstanding
this, the patients in the lower tertile had lower hypere-
mic myocardial blood flow and higher coronary resis-
tance compared to the patients in the intermediate
(average HR increase 25 bpm) and upper tertiles (aver-
age HR change 37 bpm) [25]. This observation supports
our hypothesis that inadequate peripheral hemodynamic
response to adenosine might indicate reduced coronary
vasodilatation and slightly increased coronary resistance.
Lastly, Mishra and colleagues did not test the peripheral
and coronary haemodynamic effects of a high dose infu-
sion protocol.
This study did not assess any potential advantage of
high-dose adenosine perfusion CMR on the diagnostic
performance of this technique in patients with reduced
haemodynamic response to standard adenosine dose.
Figure 2 Receiver-operator characteristic analyses to define cut-off values for age (panel A) and ejection fraction-EF (panel B) that are
predictors of inadequate response to standard dose adenosine.
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with blunted vasodilatory response would need to
undergo stress perfusion CMR twice using the standard-
and the high-dose adenosine infusion with not only
visual but also quantitative measurements of myocardial
blood flow. Nevertheless, our aim was to show feasibility
and initial safety data of the high-dose adenosine infu-
sion protocol and not to assess the potential added clini-
cal value of such an approach. Stress echocardiography
using a high dose adenosine protocol has been shown to
have incremental diagnostic value mainly by increasing
sensitivity in patients with single-vessel disease [21]. It is
conceivable that this may also be true for stress perfu-
sion CMR, but larger scale studies are needed to con-
firm our initial observations on safety of the proposed
high-dose protocol and assess its diagnostic performance
in everyday practice.
Conclusions
About one fifth of patients undergoing stress perfusion
CMR show inadequate haemodynamic response to ade-
nosine infusion at the standard dose of 140 mcg/kg/
min, for which age > 65 years and ejection fraction <
57% were independent predictors. A high-dose protocol
(up to 210 mcg/kg/min) improves the peripheral haemo-
dynamic response to adenosine, suggesting better coron-
ary vasodilatation. Our initial experience with a high
dose adenosine infusion suggests it is well tolerated and
safe, although further confirmation is needed in larger
scale studies which will test also the clinical utility of
this protocol.
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